Login / Signup

Novel early-onset Alzheimer-associated genes influence risk through dysregulation of glutamate, immune activation, and intracell signaling pathways.

Cruchaga CarlosJoseph BradleyDaniel WesternCiyang WangEder Lucio Da FonsecaAchal NeupaneJiji T KurupNIcholas RayMelissa Jean-FrancoisPriyanka GorijalaKristy BergmannJohn P BuddeEden MartinMargaret A Pericak-VanceMichael CuccaroBrian KunkleJohn MorrisDavid M HoltzmanRichard J PerrinAdam C NajJonathan L HainesGerard SchellenbergVictoria FernandezChristiane ReitzGary BeechamAlzheimer's Disease Genetics ConsortiumCharles F And Joanne Knight Alzheimer's Disease Research Ce Adrc
Published in: Research square (2024)
Alzheimer Disease (AD) is a highly polygenic disease that presents with relatively earlier onset (≤70yo; EOAD) in about 5% of cases. Around 90% of these EOAD cases remain unexplained by pathogenic mutations. Using data from EOAD cases and controls, we performed a genome-wide association study (GWAS) and trans-ancestry meta-analysis on non-Hispanic Whites (NHW, NCase=6,282, NControl=13,386), African Americans (AA NCase=782, NControl=3,663) and East Asians (NCase=375, NControl=838 CO). We identified eight novel significant loci: six in the ancestry-specific analyses and two in the trans-ancestry analysis. By integrating gene-based analysis, eQTL, pQTL and functional annotations, we nominate four novel genes that are involved in microglia activation, glutamate production, and signaling pathways. These results indicate that EOAD, although sharing many genes with LOAD, harbors unique genes and pathways that could be used to create better prediction models or target identification for this type of AD.
Keyphrases